The 7 major gaucher disease markets reached a value of USD 1,218.7 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,394.6 Million by 2035, exhibiting a growth rate (CAGR) of 1.24% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2024 |
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 1,218.7 Million |
Market Forecast in 2035
|
USD 1,394.6 Million |
Market Growth Rate 2025-2035
|
1.24% |
The gaucher disease market has been comprehensively analyzed in IMARC's new report titled "Gaucher Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Gaucher disease is a rare, inherited lysosomal storage disorder caused by mutations in the GBA gene, leading to deficient glucocerebrosidase enzyme activity. This results in the accumulation of glucocerebroside within lysosomes of macrophages, primarily affecting the spleen, liver, and bones. The disease is classified into three main types: Type 1 (non-neuronopathic) is the most common and does not affect the nervous system; Type 2 (acute neuronopathic) is severe and fatal in infancy; and Type 3 (chronic neuronopathic) presents with progressive neurological involvement. Symptoms include hepatosplenomegaly, anemia, thrombocytopenia, bone pain, fractures, lung disease, and, in severe cases, neurological impairment such as seizures and cognitive decline. Diagnosis involves enzyme activity testing in leukocytes, genetic analysis for GBA mutations, and imaging techniques like MRI to assess organ involvement and disease severity.
A significant driver for market growth would be the surging incidence of Gaucher disease, especially in persons of Ashkenazi descent. Awareness programs among others for genetic screening and early diagnostic efforts will support timely detection and management of this dreaded illness. Enzyme replacement therapy (ERT) has transformed the treatment paradigm whereby drugs like imiglucerase, velaglucerase alfa, and taliglucerase alfa have reduced the accumulation of glucocerebroside and provided symptomatic relief, thus improving the health status and quality of life of their patients. However, lifelong intravenous infusion has impeded adherence and accessibility problems. Increased acceptance of substrate reduction therapy (SRT) solutions like eliglustat and miglustat would provide an oral alternative to widen the spectrum of available treatment. More advanced avenues of targeted, potentially curative, gene therapies, chaperone-based therapies, and novel small-molecule drugs are now opening up in the treatment landscape. To hasten market growth, other mechanisms such as orphan drug incentives, increased funding for research, and strategic alliances between pharmaceutical companies are also at work. The focus placed on personalized medicine and patient-centricity is likely to create even more impetus for research and investment into new therapeutics for Gaucher disease.
IMARC Group's new report provides an exhaustive analysis of the gaucher disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, Europe has the largest patient pool for gaucher disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gaucher disease market in any manner.
Cerezyme (Imiglucerase) is a recombinant human beta-glucocerebrosidase enzyme replacement therapy that replaces missing endogenous enzyme activity, reducing the amount of glucocerebroside accumulated. It has a molecular weight of 59.3 kD, and its glycoprotein structure is modified to facilitate mannose receptor-mediated uptake into macrophages, thus enhancing therapeutic efficiency in the management of lysosomal storage disorder.
VPRIV (velaglucerase alfa) is an enzyme-activated human recombinant glucocerebrosidase treatment for Type 1 Gaucher disease, specifically treating glucocerebrosidase deficiency. It assists in alleviating symptoms of the lysosomal enzyme disorder. VPRIV is also investigated as a possible management of Type 3 Gaucher disease.
Elelyso (taliglucerase alfa) is a recombinant enzyme replacement treatment, β-glucocerebrosidase, of Type 1 Gaucher disease. It is approved in 2012 and hydrolyzes lysosomal glucocerebroside and fixes the enzyme deficits related to chronic treatment. Elelyso serves as an alternate choice to other enzyme replacement therapies in fixing the metabolic processes among affected individuals.
Cerdelga (eliglustat) is an oral inhibitor of glucosylceramide synthase for the long-term treatment of type 1 Gaucher disease. Cerdelga reduces the levels of glucosylceramide, which blocks organ infiltration and related complications. Cerdelga is administered based on CYP2D6 metabolizer status to permit best dosing.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current gaucher disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Cerezyme (Imiglucerase) | Sanofi |
VPRIV (Velaglucerase) | Takeda |
Elelyso (Taliglucerase) | Pfizer/Protalix |
Cerdelga (Eliglustat) | Sanofi |
LYM001 | Lingyi Biotech |
PR001 | Prevail Therapeutics |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Gaucher Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies